Top

Strahlentherapie und Onkologie

Published in:

01-06-2017 | Literatur kommentiert

Radiotherapie des Glioblastoms

ASCO bestätigt ASTRO-Leitlinie

Authors: Dr. med. Clemens Seidel, Prof. Dr. med. Rolf-Dieter Kortmann

Published in: Strahlentherapie und Onkologie | Issue 6/2017

Auszug

Die American Society for Radiation Oncology (ASTRO) erstellte eine evidenzbasierte Leitlinie zur Bestrahlung von Glioblastomen. Wegen der Relevanz für die American Society of Clinical Oncology (ASCO) hat diese die ASTRO-Leitlinie anhand standardisierter Kriterien einer kritischen Prüfung unterzogen. …

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed

Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6‑week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926CrossRefPubMed

Roa W, Brasher PMA, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588CrossRefPubMed

Roa W, Kepka L, Kumar N et al (2015) International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed Glioblastoma Multiforme. J Clin Oncol 33:4145–4150CrossRefPubMed

http://www.neuroonkologie.de/files/guidelines/14-gliome.pdf. Zugegriffen: 13.03.17

Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722CrossRefPubMed

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708CrossRefPubMedPubMedCentral

Herrlinger U, Schäfer N, Steinbach JP et al (2016) Bevacizumab plus Irinotecan versus Temozolomide in newly diagnosed O6-Methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol 34:1611–1619CrossRefPubMed

Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543CrossRefPubMed

Title: Radiotherapie des Glioblastoms
ASCO bestätigt ASTRO-Leitlinie
Authors: Dr. med. Clemens Seidel
Prof. Dr. med. Rolf-Dieter Kortmann
Publication date: 01-06-2017
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 6/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-017-1132-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Radiotherapie des Glioblastoms

ASCO bestätigt ASTRO-Leitlinie

Auszug

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 6/2017

Photobiomodulation therapy for the management of radiation-induced dermatitis

Prefraction displacement and intrafraction drift of the prostate due to perineal ultrasound probe pressure

Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer

BCL2 genotypes and prostate cancer survival

Whole pelvis radiotherapy for pathological node-positive prostate cancer

The impact of androgen deprivation therapy on setup errors during external beam radiation therapy for prostate cancer